Dementia is a syndrome of global cognitive de cline which inter venes with social and occupation al functioning. The two most common dementias are Alzheimer's disease (AD), caused by neuro degeneration, and vascular dementia, caused by cerebrovascular disease. These two causes often cooccur (often referred to as "mixed dementia"), especially after the age of 80. Dementia is com mon in the elderly and constitutes one of the larg est burdens for individuals and society. Its preva lence increases from around 3% at the age of 70 to 30% at the age of 85. It can be expected that the number of demented in the world will increase from less than 40 million in 2005 to more than 130 million in 2050, mainly due to an increasing number of elderly individuals, especially those aged >80 years. It is therefore important to find ways of preventing dementia.
Since the mid 1990s, a large number of obser vational studies have reported an association between previous high blood pressure and later development of dementia, including Alzheim er's disease. 1,2,3 High midlife blood pressure has also been related to the presence of senile plaques and neurofibrillary tangles, the hallmarks of AD in the brain, in late life. 4 At the same time, obser vational population studies suggest that the use of antihypertensive drugs may reduce the inci dence of AD and dementia. 2, 5, 6 Furthermore, it is reported that previous high blood pressure is only related to latelife dementia in those not on antihypertensive treatment.
3
Five antihypertensive trials with dementia as secondary endpoints have been conducted. [7] [8] [9] [10] [11] [12] All these trials observed significant reductions in the primary cardiovascular outcomes, but only the SystEur (Systolic Hypertension in Eu rope) trial 8 reported a reduction in the incidence of dementia in the treatment group. However, only 32 persons developed dementia in this trial. In the SCOPE trial, a secondary analysis showed that the treatment group had less cognitive de cline than the placebo group among those with mild cognitive impairment at baseline. 9 The first trials were mainly conducted among individuals aged <80 years, where risk for dementia is low.
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Last year, results from HYVET (The Hyperten sion in the Very Elderly Trial) were published. This was a doubleblind placebo controlled study conducted on patients aged ≥80 who had systol ic hypertension. 13 In this age group, dementia in cidence is very high. The HYVET trial had to ter minate early when inter im analyses showed re duction in both stroke and total mortality in ac tively treated patients. However, the cognitive function substudy 7 , found no statistical differ ences between treatment and placebo groups regarding dementia incidence or cognitive de cline. Thus, the results of the HYVET trial sug gest that treatment of systolic hypertension is indicated also in very elderly individuals to de crease the risk of stroke and total mortality, while shortterm treatment shows no effect on the in cidence of dementia.
Several methodo logical factors might explain the lack of beneficial effects on dementia inci dence in antihypertensive trials.
12 First, all trials were on shortterm treatment, with followups between 2 and 5 years, while observational stud ies report that blood pressure is increased 5-15 years before dementia onset, and then decreases approximately 5 years before dementia onset.
1,2,3
Crosssectional studies and studies with short fol lowups (i.e. <5 years) report associations between low blood pressure and prevalent or incident de mentia. This low blood pressure is probably sec ondary to the brain changes occurring in demen tia disorders, which may affect blood pressure reg ulating areas. 2 Thus, lengths of followup conduct ed in trials might have been too short to detect an effect on the incidence of dementia. Therefore, no conclusions can be made about the effects of longterm antihypertensive treatment on de mentia incidence. For ethical reasons, it may not be possible to conduct longterm placebocon trolled studies in the future, due to the benefit of treatment on cardiovascular outcomes. Oth er methodo logical factors that might explain the lack of treatment effect on dementia inci dence includes that antihypertensive trials have mainly included mentally very healthy partici pants at baseline. This group is expected to have a low shortterm incidence of dementia and a ceil ing effect may occur when change in test score is measured. Other methodo logical issues include practice or learning effects, selective dropout in relation to dementia, and difficulties to diag nose dementia reliably in large trials. 12 No antihypertensive trial has been conduct ed in hypertensives with Alzheimer's disease. Al though individuals with Alzheimer's disease as a group have lower blood pressure than nonde mented controls, a large proportion may still have hypertension. Two observational studies report that cognitive decline was faster in Alzheimer patients with hypertension at baseline 14,15 , and in one of these studies those on antihypertensive drugs had a slower decline 15 . Observational stud ies also report that Alzheimer patients treated for hypertension have better cognitive function than those without. 16, 17 This indicates that antihyper tensive treatment may be beneficial on cognition in demented individuals, but the results need to be taken cautiously until confirmed in ran domized controlled trials. However, it could be discussed whether randomized controlled trials with antihypertensives are ethical in demented individuals with hypertension, due to the bene ficial effect of antihypertensives on cardiovascu lar outcomes shown in large trials.
There are some important clinical implications of these findings. First, antihypertensive trials in the elderly, including those aged >80 years, show that shortterm antihypertensive treatment is beneficial in relation to stroke and total mor tality. It is thus important to detect and treat hy pertension in the elderly irrespective of whether it prevents dementia or not, as it might prevent cardiovascular disease. Second, antihypertensive treatment seems to be safe in relation to brain function in the elderly. There is a common be lief among many doctors that treatment of hy pertension in the very elderly might have nega tive effects on brain function by reducing cerebral blood flow. In fact, this common concept has no empirical support. No trial so far has found that treatment of hypertension increased risk of de mentia or cognitive decline. Furthermore, obser vational population studies suggest that the use of antihypertensive drugs may reduce the inci dence of AD and dementia 2, 5, 6 , and no study re ports that antihypertensive treatment increases risk. Finally, most individuals with hypertension or dementia are not detected by the health care system. Hypertension is important to detect due to its effect on cardiovascular health. Cognitive impairment and dementia is important to detect in elderly hypertensives due to its potential im pact on the patient's compliance with treatment. It also needs to be emphasized that when detect ed, hypertension needs to be treated also in de mented individuals.
